Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Piribedil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.80 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.80 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.80 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.80 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.80 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.80 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.80 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.80 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piribedil SCHEMBL1320658 | 1.00 | LMNA (1.00) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL5605887 | 0.90 | MEN1 (1.00) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL150101 | 0.90 | MEN1 (1.00) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL29359749 | 0.90 | MEN1 (1.00) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL14973600 | 0.89 | MEN1 (0.97) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL3765569 | 0.89 | MEN1 (0.97) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL27036877 | 0.89 | MEN1 (0.97) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL28260221 | 0.86 | MEN1 (0.88) | LMNAPMP22MEN1KMT2AUSP2 | |
| Piribedil SCHEMBL1652330 | 0.86 | MAPK1 (0.82) | LMNAPMP22MEN1KMT2AUSP2 | |
| SCHEMBL23652830 | 0.82 | MEN1 (0.85) | LMNAPMP22MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200046693-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | claimed |
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210315885-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-11065247-B2 | Compositions and methods for the treatment of Zellweger spectrum disorder | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-20 | — | — | US | disclosed |
| US-20200046693-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-20180000814-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | NATIONAL INSTITUTES OF HEALTH | 2018-01-04 | — | — | US | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | HTR1A 31/4885ADRA2A 40/4885DRD2 19/4885 |
| US-20200046693-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | HSD17B4, CYP27A1, OAT | HTR1A 4513/4885ADRA2A 3704/4885DRD2 4582/4885 |
| US-11065247-B2 | Compositions and methods for the treatment of Zellweger spectrum disorder | HSD17B4, CYP27A1, OAT | HTR1A 4513/4885ADRA2A 3704/4885DRD2 4582/4885 |
| US-20210315885-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | HSD17B4, CYP27A1, OAT | HTR1A 4513/4885ADRA2A 3704/4885DRD2 4582/4885 |
| US-20180000814-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER | HSD17B4, CYP27A1, OAT | HTR1A 4513/4885ADRA2A 3704/4885DRD2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.